Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513329 · ClinicalTrials.gov registry record · Phase 2
Stellate Ganglion Block (SGB) For Women for Breast Cancer
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02513329 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 37 participants.
The verdict
NCT02513329, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on anti-estrogens and are seeking relief from moderate to very severe VMS that are adversely affecting health and wellbeing. Women with breast cancer on Tamoxifen, aromatase inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMS) with moderate to very severe VMS will be enrolled as participants in this study.
Interventions
- DRUG Saline
- DRUG Bupivicaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-07 |
| Est. Completion | 2020-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513329
The ClinicalTrials.gov registry entry for NCT02513329 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02513329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513329 about?
NCT02513329 is a clinical study titled "Stellate Ganglion Block (SGB) For Women for Breast Cancer". Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on anti-estrogens and are seeking relief from moderate to very severe VMS that are ad...
What is the current status of trial NCT02513329?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2015-07. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02513329?
The interventions under investigation include: Saline (DRUG), Bupivicaine (DRUG).
Who is sponsoring clinical trial NCT02513329?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.